Uterine Fibroids Treatment Drugs Market, By Fibroid Type, By Drug Type, By Distribution Channel, By Geography

Description

The uterine fibroids treatment drugs market is estimated to be valued at USD 1.87 Bn in 2024 and is expected to reach USD 3.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.87 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	7.90%	2031 Value Projection:	US$ 3.19 Bn

Figure 1.Uterine Fibroids Treatment Drugs Market Share (%), By Region, 2024

Uterine Fibroids Treatment Drugs Market - IMG1

Uterine fibroids are non-cancerous tumors that grow in or on a woman's uterus. Symptoms caused by fibroids vary in severity and include heavy or painful periods, pressure or pain in the lower abdomen, frequent urination, etc. Over-the-counter medications like ibuprofen can help relieve symptoms but do not address the underlying cause. Surgical procedures are an option but carry risks. Therefore, drug therapies that can shrink or eliminate fibroids without surgery present an attractive option for many patients. The global uterine fibroids treatment drugs market offers promising growth opportunities as researchers work to develop novel therapies.

Market Dynamics:

The growing prevalence of uterine fibroids among women coupled with the demand for non-invasive treatment options is a key factor fueling the uterine fibroids treatment drugs market growth. As per Office on Women's Health press release published in February 2021, around 20-80% women develop fibroids by the age of 50. Moreover, the limitations and risks associated with surgical procedures are further driving research into pharmaceutical therapies. However, the high costs involved in drug development pose a challenge. Additionally, lack of awareness about fibroid treatment options in developing nations also restrains market expansion. Meanwhile, emerging oral therapies in the clinical trial pipeline are expected to provide new opportunities.

Key Features of the Study:

This report provides an in-depth analysis of the global uterine fibroids treatment drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global uterine fibroids treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Myovant Sciences, Pfizer, Bayer AG, AstraZeneca, AbbVie Inc., Abbott Healthcare Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Gedeon Richter plc, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., TerSera Therapeutics, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Biocon Biologics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global uterine fibroids treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global uterine fibroids treatment drugs market.

Market Segmentation

Fibroid Type:
- Intramural fibroids
- Submucosal fibroids
- Subserosal fibroids
- Others
Drug Type:
- Gonadotropin-releasing hormone (GnRH) antagonists
- Gonadotropin-releasing hormone (GnRH) agonists
- Progesterone & Contraceptives
- Hormonal Medications
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Myovant Sciences
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics

Product Code: CMI6788

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Fibroid Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Uterine Fibroids Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 impact on the market

5. Global Uterine Fibroids Treatment Drugs Market, By Fibroid Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Intramural fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Submucosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Subserosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Uterine Fibroids Treatment Drugs Market, By Drug Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Gonadotropin-releasing hormone (GnRH) antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Gonadotropin-releasing hormone (GnRH) agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Progesterone & Contraceptives
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Hormonal Medications
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Uterine Fibroids Treatment Drugs Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Uterine Fibroids Treatment Drugs Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Myovant Sciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact